Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Marketing Practices Under Investigation By Philadelphia U.S. Attorney

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon will turn over documents from 1998 to the present regarding "sales and promotional practices" for Provigil, Gabitril and Actiq.

You may also be interested in...



Cephalon Settles Federal Investigation Of Marketing Practices For $425 Million

Cephalon enters into a corporate integrity agreement with HHS Inspector General, which likely will be in line with its existing compliance program, firm tells “The Pink Sheet” DAILY.

Cephalon Settles Federal Investigation Of Marketing Practices For $425 Million

Cephalon enters into a corporate integrity agreement with HHS Inspector General, which likely will be in line with its existing compliance program, firm tells “The Pink Sheet” DAILY.

Cephalon’s Gabitril Marketing Scaled Back Pending Anxiety Trial Results

Sales of Gabitril declined 36% to $15.7 mil. in the second quarter.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel